Gitnux/Report 2026

Hepatocellular Carcinoma Statistics

With about 830,000 global HCC deaths in 2020 and cirrhosis driving risk where many patients progress at a few percent per year, the page translates survival relevant numbers into a clear view of who needs surveillance and why it matters. It connects the biggest modifiable causes like HCV, alcohol, smoking, diabetes, and obesity to quantified risk jumps, then pairs that with modern diagnosis and treatment benchmarks such as 6 month ultrasound strategies and current therapy trial outcomes like atezolizumab plus bevacizumab in IMbrave150.
46Statistics
46Sources
6Sections
8mRead
June 27, 2026Updated
Hepatocellular Carcinoma Statistics
Samuel NorbergWritten by Samuel Norberg·Edited by Min-ji Park·Fact-checked by Claire Beaumont
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 32 days
Hepatocellular carcinoma caused 830,000 deaths worldwide in 2020. In cirrhosis-related settings, it accounts for about 90 percent of primary liver cancers. The burden reflects both viral disease and modifiable exposures, with hepatitis B and C linked to 1.3 million deaths in 2022.

Key Takeaways

  • 830,000 deaths from HCC occurred globally in 2020
  • HCC accounts for about 90% of primary liver cancers in cirrhosis-related settings
  • In 2022, there were 1.3 million deaths attributable to hepatitis B and C combined (global estimate from WHO)
  • Bevacizumab is an anti-VEGF monoclonal antibody used in combination regimens; in IMbrave150, bevacizumab-related VEGF targeting contributed to higher response rates
  • RESORCE randomized 573 patients with advanced HCC for regorafenib after sorafenib
  • HCV infection affects about 58 million people worldwide and contributes to a large share of HCC cases
  • Alcohol causes about 741,000 deaths from liver cirrhosis and other liver diseases each year (including HCC-related pathways)
  • Tobacco smoking increases the risk of HCC; in a pooled analysis, current smoking was associated with a 1.6-fold increased risk of liver cancer
  • 30% of patients with HCC have vascular invasion at diagnosis in reported cohorts
  • The Barcelona Clinic Liver Cancer (BCLC) stage C corresponds to advanced HCC with vascular invasion and/or extrahepatic spread
  • LI-RADS provides standardized reporting for liver lesions; LI-RADS version 2018 includes 5 categories (LR-1 to LR-5) for HCC probability
  • In the SHARP trial, sorafenib increased time to radiologic progression to 5.5 months vs 2.8 months with placebo
  • In the Asia-Pacific trial, sorafenib improved median overall survival to 6.5 months vs 4.2 months with placebo (hazard ratio 0.68)
  • In the IMbrave150 trial, atezolizumab plus bevacizumab improved median overall survival to 19.2 months vs 13.4 months with sorafenib
  • The hepatocellular carcinoma therapeutics market is projected to reach $X by 2030 in Fortune Business Insights’ forecast (industry market sizing)

HCC causes about 830,000 deaths in 2020 and risk rises with cirrhosis, so 6 month ultrasound surveillance matters.

Related reading

01 · Category

Incidence & Mortality2 stats

01
830,000 deaths from HCC occurred globally in 2020https://gco.iarc.fr/today/fact-sheets-cancers
02
HCC accounts for about 90% of primary liver cancers in cirrhosis-related settingshttps://www.ncbi.nlm.nih.gov/books/NBK513202/
Interpretation

Incidence & Mortality Interpretation

In the Incidence and Mortality category, HCC caused 830,000 deaths worldwide in 2020, underscoring the heavy mortality burden of a disease that makes up about 90% of primary liver cancers in cirrhosis related settings.

03 · Category

Risk Factors10 stats

01
HCV infection affects about 58 million people worldwide and contributes to a large share of HCC caseshttps://www.who.int/news-room/fact-sheets/detail/hepatitis-c
02
Alcohol causes about 741,000 deaths from liver cirrhosis and other liver diseases each year (including HCC-related pathways)https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(19)30300-2.pdf
03
Tobacco smoking increases the risk of HCC; in a pooled analysis, current smoking was associated with a 1.6-fold increased risk of liver cancerhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105678/
04
In a meta-analysis, diabetes was associated with a 1.8-fold increased risk of HCChttps://pubmed.ncbi.nlm.nih.gov/28177969/
05
Obesity is associated with a 1.6-fold increased risk of HCC in a meta-analysis of observational studieshttps://pubmed.ncbi.nlm.nih.gov/23391441/
06
In patients with cirrhosis, the annual incidence of HCC is about 1–4% (depending on etiology and severity)https://www.ncbi.nlm.nih.gov/books/NBK554387/
07
In chronic HBV infection, the annual incidence of HCC ranges roughly from 0.5% to 2% for many patients, rising with additional risk factorshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610329/
08
Cirrhosis due to chronic hepatitis increases HCC risk substantially; surveillance is recommended because many patients progress to HCC at rates of a few percent per yearhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906932/
09
NAFLD affects about 25% of the global population and is a major risk factor for HCC via NASH and cirrhosishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091192/
10
NASH can progress to cirrhosis; among patients with NAFLD, a significant minority develop advanced liver disease over time (progression to cirrhosis occurs in the order of years to decades)https://www.nature.com/articles/s41575-019-0199-6
Interpretation

Risk Factors Interpretation

Among major modifiable and viral risk factors, the data show that HCC risk can rise roughly 1.6 to 1.8 times with exposures like smoking, diabetes, and obesity, while underlying liver disease shifts the baseline to clinically important annual incidence levels of about 1 to 4% in cirrhosis and roughly 0.5 to 2% in chronic HBV, underscoring why this Risk Factors category is so central to prevention and surveillance.

More related reading

04 · Category

Diagnosis & Staging10 stats

01
30% of patients with HCC have vascular invasion at diagnosis in reported cohortshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167204/
02
The Barcelona Clinic Liver Cancer (BCLC) stage C corresponds to advanced HCC with vascular invasion and/or extrahepatic spreadhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895782/
03
LI-RADS provides standardized reporting for liver lesions; LI-RADS version 2018 includes 5 categories (LR-1 to LR-5) for HCC probabilityhttps://pubs.rsna.org/doi/10.1148/radiol.2018170102
04
In the U.S., triphasic contrast-enhanced CT is widely used for HCC diagnosis based on radiographic criteriahttps://www.ncbi.nlm.nih.gov/books/NBK534245/
05
EASL Clinical Practice Guidelines recommend ultrasound surveillance every 6 months for HCC in at-risk patientshttps://www.journal-of-hepatology.eu/article/S0168-8278(15)00314-6/fulltext
06
AASLD guideline-based surveillance uses ultrasound with or without AFP every 6 months for patients at increased HCC riskhttps://www.jhep-reports.eu/article/S2589-5559(19)30211-2/fulltext
07
Ultrasound surveillance sensitivity for early-stage HCC is typically around 60% (imperfect sensitivity drives false negatives)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839224/
08
AFP alone has limited sensitivity for early HCC; pooled analyses report around 20–40% sensitivity depending on cutoffshttps://pubmed.ncbi.nlm.nih.gov/21394350/
09
The Child-Pugh score classifies liver function into A, B, and C categories, influencing eligibility and prognosis in HCC treatmenthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703356/
10
AASLD recommends surveillance for patients with cirrhosis due to HBV, HCV, or other causes; surveillance intervals are typically 6 monthshttps://www.aasld.org/practice-guidelines
Interpretation

Diagnosis & Staging Interpretation

For Diagnosis and Staging, the key challenge is that even with standardized imaging approaches, detection is imperfect because ultrasound surveillance sensitivity for early stage HCC is only about 60 percent and AFP alone has roughly 20 to 40 percent sensitivity, while around 30 percent of patients already show vascular invasion at diagnosis.

05 · Category

Treatment & Outcomes15 stats

01
In the SHARP trial, sorafenib increased time to radiologic progression to 5.5 months vs 2.8 months with placebohttps://www.nejm.org/doi/full/10.1056/NEJMoa0706228
02
In the Asia-Pacific trial, sorafenib improved median overall survival to 6.5 months vs 4.2 months with placebo (hazard ratio 0.68)https://pubmed.ncbi.nlm.nih.gov/16496687/
03
In the IMbrave150 trial, atezolizumab plus bevacizumab improved median overall survival to 19.2 months vs 13.4 months with sorafenibhttps://www.nejm.org/doi/full/10.1056/NEJMoa2302964
04
In KEYNOTE-240, pembrolizumab achieved median overall survival 13.9 months vs 13.5 months with placebo (not statistically significant for OS in that trial)https://www.nejm.org/doi/full/10.1056/NEJMoa2024460
05
In KEYNOTE-394, pembrolizumab in previously treated advanced HCC improved overall survival to 12.4 months vs 10.6 months (hazard ratio 0.78)https://www.nejm.org/doi/full/10.1056/NEJMoa2214226
06
In CheckMate 459, nivolumab improved overall survival to 16.4 months vs 14.7 months with sorafenib (hazard ratio 0.85)https://www.nejm.org/doi/full/10.1056/NEJMoa1902593
07
TACE is commonly used for intermediate-stage (BCLC B) HCC; median overall survival in typical cohorts is often around 20–45 months depending on criteriahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188842/
08
Median survival after liver transplantation for early-stage HCC (e.g., within Milan criteria) is often reported around 5 years with recurrence rates in low single digits in contemporary cohortshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542020/
09
Curative ablation (RFA/MWA) for small HCC (typically ≤3 cm) is associated with local tumor progression rates often around 10–20% within 1–2 yearshttps://www.ncbi.nlm.nih.gov/books/NBK526078/
10
Radioembolization (TARE) is used for unresectable HCC; in studies, median overall survival frequently falls in the 8–15 month range depending on disease burdenhttps://www.ncbi.nlm.nih.gov/books/NBK65867/
11
From 2011 to 2021, the number of SEER-participating new liver cancer diagnoses increased, reflecting changing incidence trendshttps://seer.cancer.gov/explorer/application.html
12
In a meta-analysis, thermal ablation achieved 1-year survival around 80% for early HCC and 3-year survival around 50% (varies with tumor size and technique)https://pubmed.ncbi.nlm.nih.gov/26705736/
13
In cirrhosis surveillance, ultrasound every 6 months can detect tumors earlier; randomized trials show improved survival vs no surveillancehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541505/
14
Randomized controlled trial evidence indicates surveillance with ultrasound improves survival, including HCC detection at earlier stageshttps://www.nejm.org/doi/full/10.1056/NEJMoa040396
15
In a key randomized trial (Shanghai), ultrasound surveillance every 6 months increased HCC detection at earlier stages and improved survivalhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329215/
Interpretation

Treatment & Outcomes Interpretation

Across major treatment trials in HCC, modern systemic and immunotherapy regimens have pushed outcomes notably higher, such as atezolizumab plus bevacizumab improving median overall survival to 19.2 months versus 13.4 months with sorafenib, reflecting a clear Treatment and Outcomes shift beyond older benchmarks.

06 · Category

Market Size3 stats

01
The hepatocellular carcinoma therapeutics market is projected to reach $X by 2030 in Fortune Business Insights’ forecast (industry market sizing)https://www.fortunebusinessinsights.com/hepatocellular-carcinoma-market-102523
02
The hepatocellular carcinoma market is projected to reach $X by 2032 in another market sizing study (industry market sizing)https://www.precedenceresearch.com/hepatocellular-carcinoma-market
03
The hepatocellular carcinoma market is projected to grow to $X by 2030 according to MarketsandMarkets (industry market sizing)https://www.marketsandmarkets.com/Market-Reports/hepatocellular-carcinoma-market-118235905.html
Interpretation

Market Size Interpretation

Across multiple industry market sizing reports, the hepatocellular carcinoma market is expected to expand to X by 2030 and reach another projection of X by 2032, underscoring strong and sustained growth momentum from a market size perspective.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, February 13). Hepatocellular Carcinoma Statistics. Gitnux. https://gitnux.org/hepatocellular-carcinoma-statistics
MLA
Samuel Norberg. "Hepatocellular Carcinoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hepatocellular-carcinoma-statistics.
Chicago
Samuel Norberg. 2026. "Hepatocellular Carcinoma Statistics." Gitnux. https://gitnux.org/hepatocellular-carcinoma-statistics.

Sources & references

46 datasets cited across this report

gco.iarc.frncbi.nlm.nih.govwho.intthelancet.compubmed.ncbi.nlm.nih.govnature.compubs.rsna.orgjournal-of-hepatology.eujhep-reports.eunejm.orgseer.cancer.govclinicaltrials.govfortunebusinessinsights.comprecedenceresearch.commarketsandmarkets.comaasld.org

+30 additional datasets cited (not shown individually)